Orexo AB (publ) (STO:ORX)
Sweden · Delayed Price · Currency is SEK 26.85
-1.35 (-4.79%)
Mar 2, 2026, 5:24 PM CET
Orexo AB Revenue
In the year 2025, Orexo AB had annual revenue of 26.00M SEK, down -95.59%. Orexo AB had revenue of 3.30M in the quarter ending December 31, 2025, a decrease of -97.94%.
Revenue
26.00M
Revenue Growth
-95.59%
P/S Ratio
38.10
Revenue / Employee
361.11K
Employees
72
Market Cap
990.58M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.00M | -564.00M | -95.59% |
| Dec 31, 2024 | 590.00M | -48.80M | -7.64% |
| Dec 31, 2023 | 638.80M | 14.50M | 2.32% |
| Dec 31, 2022 | 624.30M | 59.30M | 10.50% |
| Dec 31, 2021 | 565.00M | -98.60M | -14.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioGaia AB | 1.54B |
| EQL Pharma AB | 425.75M |
| Cinclus Pharma Holding AB | 57.47M |
| Nanexa AB | 55.94M |
| Enzymatica AB | 53.90M |
| Cereno Scientific AB | 46.66M |
| Moberg Pharma AB | 13.54M |
| Klaria Pharma Holding AB (publ.) | 8.99M |
Orexo AB News
- 25 days ago - Orexo AB (publ) (ORXOY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Orexo AB (publ) (ORXOY) Discusses Divestment of US Rights to Zubsolv and Transition Agreement with Dexcel Pharma Transcript - Seeking Alpha
- 4 months ago - Orexo AB (publ) (ORXOY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication - PRNewsWire
- 9 months ago - Orexo to present clinical data for OX640 at the EAACI Congress - PRNewsWire
- 11 months ago - Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology - PRNewsWire
- 1 year ago - Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis - PRNewsWire
- 1 year ago - Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology - PRNewsWire